At 10:20 IST, the barometer index, the S&P BSE Sensex, jumped 520.77 points or 1% at 52,719.79. The Nifty 50 index gained 146.35 points or 0.94% at 15,778.75.
In broader market, the S&P BSE Mid-Cap index surged 0.82% while the S&P BSE Small-Cap index was gained 1.35%.
The market breadth, indicating the overall health of the market, was strong. On the BSE, 2242 shares rose and 703 shares fell. A total of 127 shares were unchanged.
COVID-19 Update:
Total COVID-19 confirmed cases worldwide stood at 191,951,455 with 4,126,444 global deaths.
India reported 409,394 active cases of COVID-19 infection and 418,987 deaths, according to the data from the Ministry of Health and Family Welfare, Government of India.
Results Today:
Hindustan Unilever (up 1.54%), UltraTech Cement (up 0.89%), Bajaj Auto (up 0.49%), Agro Tech Foods (up 5.55%), Biocon (down 1.2%), Can Fin Homes (up 1.35%), CSB Bank (down 1.27%), Heidelbergcement India (up 2.24%), Hindustan Zinc (up 1.02%), ICICI Lombard General Insurance Company (up 1.48%), Indian Energy Exchange (up 2.36%), IIFL Securities (up 1.91%), IndiaMART InterMESH (down 2.46%), Bank of Maharashtra (down 0.85%), Mahindra EPC Irrigation (down 1%), Mphasis (up 2.88%), Persistent Systems (up 1.6%), Music Broadcast (up 0.4%), Sterlite Technologies (up 4.95%) and Wockhardt (up 2.49%) will announce their quarterly earnings today.
Buzzing Index:
The Nifty Realty index jumped 2.93% to 400.55 and was a top gainer on NSE Sectoral Indices. The index rebounded after losing 2.53% in previous trading session.
Indiabulls Real Estate (up 4.27%), Brigade Enterprises (up 3.7%), Phoenix Mills (up 3.46%), Sunteck Realty (up 2.78%) and DLF (up 2.62%), Godrej Properties (up 2.58%), Mahindra Lifespace Developers (up 2.52%), Prestige Estates Projects (up 2.24%), Oberoi Realty (up 1.37%) and Sobha (up 0.58%) advanced.
Earnings Impact:
Gland Pharma soared 5.38% after the company's net profit jumped 11.81% to Rs 350.65 crore on 30.50% increase in revenue from operations to Rs 1,153.90 crore in Q1 FY22 over Q1 FY21. The growth in revenue was contributed from a mix of launch of new products and volume growth in existing products. The key markets, US, Canada, Europe and Australia registered a growth of 16% and accounted for 61% of the revenue during Q1 FY22. This performance is driven by growth of key products like Micafungin, Enoxaparin, Heparin, Dexmedetomidine and new product launches. Profit before tax surged 12.34% to Rs 471.84 crore in Q1 FY22 as against Rs 420 crore in Q1 FY21. The Q1 earnings was declared on Wednesday, 21 July 2021.
CRISIL jumped 4.31%. The credit rating agency recorded 51.9% increase in net profit to Rs 100.8 crore on 12% rise in income from operations to Rs 528.51 crore in Q2 June 2021 over Q2 June 2020. The board of CRISIL has approved the payment of interim dividend of Rs 8 per equity share for the financial year ending 31 December 2021, which will be paid on 18 August 2021.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
